<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34498840</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2373-8227</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>7</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Oct</Month>
              <Day>08</Day>
            </PubDate>
          </JournalIssue>
          <Title>ACS infectious diseases</Title>
          <ISOAbbreviation>ACS Infect Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Inhibitors of L-Type Calcium Channels Show Therapeutic Potential for Treating SARS-CoV-2 Infections by Preventing Virus Entry and Spread.</ArticleTitle>
        <Pagination>
          <StartPage>2807</StartPage>
          <EndPage>2815</EndPage>
          <MedlinePgn>2807-2815</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">acsinfecdis.1c00023</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1021/acsinfecdis.1c00023</ELocationID>
        <Abstract>
          <AbstractText>COVID-19 is caused by a novel coronavirus, the severe acute respiratory syndrome coronavirus (CoV)-2 (SARS-CoV-2). The virus is responsible for an ongoing pandemic and concomitant public health crisis around the world. While vaccine development is proving to be highly successful, parallel drug development approaches are also critical in the response to SARS-CoV-2 and other emerging viruses. Coronaviruses require Ca<sup>2+</sup> ions for host cell entry, and we have previously shown that Ca<sup>2+</sup> modulates the interaction of the viral fusion peptide with host cell membranes. In an attempt to accelerate drug repurposing, we tested a panel of L-type calcium channel blocker (CCB) drugs currently developed for other conditions to determine whether they would inhibit SARS-CoV-2 infection in cell culture. All the CCBs tested showed varying degrees of inhibition, with felodipine and nifedipine strongly limiting SARS-CoV-2 entry and infection in epithelial lung cells at concentrations where cell toxicity was minimal. Further studies with pseudotyped particles displaying the SARS-CoV-2 spike protein suggested that inhibition occurs at the level of virus entry. Overall, our data suggest that certain CCBs have the potential to treat SARS-CoV-2 infections and are worthy of further examination for possible treatment of COVID-19.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Straus</LastName>
            <ForeName>Marco R</ForeName>
            <Initials>MR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology &amp; Immunology, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bidon</LastName>
            <ForeName>Miya K</ForeName>
            <Initials>MK</Initials>
            <AffiliationInfo>
              <Affiliation>Robert Frederick Smith School of Chemical &amp; Biomolecular Engineering, Cornell University, Ithaca, New York 14853, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Tiffany</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Robert Frederick Smith School of Chemical &amp; Biomolecular Engineering, Cornell University, Ithaca, New York 14853, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jaimes</LastName>
            <ForeName>Javier A</ForeName>
            <Initials>JA</Initials>
            <Identifier Source="ORCID">0000-0001-6706-092X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology &amp; Immunology, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Whittaker</LastName>
            <ForeName>Gary R</ForeName>
            <Initials>GR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Microbiology &amp; Immunology, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853, United States.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Master of Public Health Program, Cornell University, Ithaca, New York 14853, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Daniel</LastName>
            <ForeName>Susan</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-7773-0835</Identifier>
            <AffiliationInfo>
              <Affiliation>Robert Frederick Smith School of Chemical &amp; Biomolecular Engineering, Cornell University, Ithaca, New York 14853, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>09</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>ACS Infect Dis</MedlineTA>
        <NlmUniqueID>101654580</NlmUniqueID>
        <ISSNLinking>2373-8227</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020746">Calcium Channels, L-Type</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020746" MajorTopicYN="N">Calcium Channels, L-Type</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004364" MajorTopicYN="Y">Pharmaceutical Preparations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053586" MajorTopicYN="N">Virus Internalization</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">COVID-19 treatment</Keyword>
        <Keyword MajorTopicYN="Y">Ca2+</Keyword>
        <Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword>
        <Keyword MajorTopicYN="Y">calcium channel blockers</Keyword>
        <Keyword MajorTopicYN="Y">viral entry</Keyword>
        <Keyword MajorTopicYN="Y">viral inhibition</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no competing financial interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>9</Day>
          <Hour>12</Hour>
          <Minute>12</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34498840</ArticleId>
        <ArticleId IdType="pmc">PMC8442615</ArticleId>
        <ArticleId IdType="doi">10.1021/acsinfecdis.1c00023</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Su S.; Wong G.; Shi W.; Liu J.; Lai A. C. K.; Zhou J.; Liu W.; Bi Y.; Gao G. F.
Epidemiology, Genetic Recombination, and Pathogenesis of
Coronaviruses. Trends Microbiol.
2016, 24, 490–502. 10.1016/j.tim.2016.03.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tim.2016.03.003</ArticleId>
            <ArticleId IdType="pmc">PMC7125511</ArticleId>
            <ArticleId IdType="pubmed">27012512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Whittaker G. R.; Daniel S.; Millet J. K.
Coronavirus entry: how we arrived at SARS-CoV-2. Curr. Opin. Virol.
2021, 47, 113–120. 10.1016/j.coviro.2021.02.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.coviro.2021.02.006</ArticleId>
            <ArticleId IdType="pmc">PMC7942143</ArticleId>
            <ArticleId IdType="pubmed">33744490</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Health Organization . Coronavirus
Disease 2019 (COVID-19) Situation Reports - 72; WHO Situation report,
2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Wu F.; Zhao S.; Yu B.; Chen Y. M.; Wang W.; Song Z. G.; Hu Y.; Tao Z. W.; Tian J. H.; Pei Y. Y.; Yuan M. L.; Zhang Y. L.; Dai F. H.; Liu Y.; Wang Q. M.; Zheng J. J.; Xu L.; Holmes E. C.; Zhang Y. Z.
A new coronavirus associated with human respiratory disease in
China. Nature
2020, 579, 265–269. 10.1038/s41586-020-2008-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-020-2008-3</ArticleId>
            <ArticleId IdType="pmc">PMC7094943</ArticleId>
            <ArticleId IdType="pubmed">32015508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>WHO . COVID-19 vaccine tracker and
landscape; Vol 3, 2020. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.</Citation>
        </Reference>
        <Reference>
          <Citation>Grein J.; Ohmagari N.; Shin D.; Diaz G.; Asperges E.; Castagna A.; Feldt T.; Green G.; Green M. L.; Lescure F. X.; Nicastri E.; Oda R.; Yo K.; Quiros-Roldan E.; Studemeister A.; Redinski J.; Ahmed S.; Bernett J.; Chelliah D.; Chen D.; Chihara S.; Cohen S. H.; Cunningham J.; Monforte A. D.; Ismail S.; Kato H.; Lapadula G.; L’Her E.; Maeno T.; Majumder S.; Masssari M.; Mora-Rillo M.; Mutoh Y.; Nguyen D.; Verweij E.; Zoufaly A.; Osinusi A. O.; DeZure A.; Zhao Y.; Zhong L.; Chokkalingam A.; Elboudwarej E.; Telep L.; Timbs L.; Henne I.; Sellers S.; Cao H.; Tan S. K.; Winterbourne L.; Desai P.; Mera R.; Gaggar A.; Myers R. P.; Brainard D. M.; Childs R.; Flanigan T.
Compassionate Use of Remdesivir for Patients with Severe
Covid-19. N. Engl. J. Med.
2020, 382, 2327–2336. 10.1056/NEJMoa2007016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2007016</ArticleId>
            <ArticleId IdType="pmc">PMC7169476</ArticleId>
            <ArticleId IdType="pubmed">32275812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang T.; Bidon M.; Jaimes J. A.; Whittaker G. R.; Daniel S.
Coronavirus membrane fusion mechanism offers a potential target for
antiviral development. Antiviral Res.
2020, 178, 104792.10.1016/j.antiviral.2020.104792.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.antiviral.2020.104792</ArticleId>
            <ArticleId IdType="pmc">PMC7194977</ArticleId>
            <ArticleId IdType="pubmed">32272173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang G.; Tan Z.; Zhou L.; Yang M.; Peng L.; Liu J.; Cai J.; Yang R.; Han J.; Huang Y.; He S.
Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting
Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in
Patients with COVID-19 and Hypertension: A Single-Center Retrospective
Study. Hypertension
2020, 76, 51–58. 10.1161/HYPERTENSIONAHA.120.15143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.120.15143</ArticleId>
            <ArticleId IdType="pubmed">32348166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoffmann M.; Kleine-Weber H.; Schroeder S.; Krüger N.; Herrler T.; Erichsen S.; Schiergens T. S.; Herrler G.; Wu N. H.; Nitsche A.; Müller M. A.; Drosten C.; Pöhlmann S.
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a
Clinically Proven Protease Inhibitor. Cell
2020, 181, 271–280.e8. 10.1016/j.cell.2020.02.052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId>
            <ArticleId IdType="pmc">PMC7102627</ArticleId>
            <ArticleId IdType="pubmed">32142651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Vries R. D.; Schmitz K. S.; Bovier F. T.; Predella C.; Khao J.; Noack D.; Haagmans B. L.; Herfst S.; Stearns K. N.; Drew-Bear J.; Biswas S.; Rockx B.; McGill G.; Dorrello N. V.; Gellman S. H.; Alabi C. A.; de Swart R. L.; Moscona A.; Porotto M.
Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2
transmission in ferrets. Science (Washington, DC, U. S.)
2021, 371, 137910.1126/science.abf4896.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.abf4896</ArticleId>
            <ArticleId IdType="pmc">PMC8011693</ArticleId>
            <ArticleId IdType="pubmed">33597220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang T.; Jaimes J. A.; Bidon M. K.; Straus M. R.; Daniel S.; Whittaker G. R.
Proteolytic Activation of SARS-CoV-2 Spike at the S1/S2 Boundary: Potential
Role of Proteases beyond Furin. ACS Infect. Dis.
2021, 7, 264.10.1021/acsinfecdis.0c00701.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsinfecdis.0c00701</ArticleId>
            <ArticleId IdType="pmc">PMC7839419</ArticleId>
            <ArticleId IdType="pubmed">33432808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang C.; Li W.; Drabek D.; Okba N. M. A.; van Haperen R.; Osterhaus A. D. M. E.; van Kuppeveld F. J. M.; Haagmanss B. L.; Grosveld F.; Bosch B. J.
A human monoclonal antibody blocking SARS-CoV-2 infection. Nat. Commun.
2020, 11, 1.10.1038/s41467-020-16256-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-020-16256-y</ArticleId>
            <ArticleId IdType="pmc">PMC7198537</ArticleId>
            <ArticleId IdType="pubmed">32366817</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lai A. L.; Millet J. K.; Daniel S.; Freed J. H.; Whittaker G. R.
The SARS-CoV Fusion Peptide Forms an Extended Bipartite Fusion Platform
that Perturbs Membrane Order in a Calcium-Dependent Manner. J. Mol. Biol.
2017, 429, 3875–3892. 10.1016/j.jmb.2017.10.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jmb.2017.10.017</ArticleId>
            <ArticleId IdType="pmc">PMC5705393</ArticleId>
            <ArticleId IdType="pubmed">29056462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Straus M. R.; Tang T.; Lai A. L.; Flegel A.; Bidon M. K.; Freed J. H.; Daniel S.; Whittaker G. R.
Ca 2+ ions promote fusion of Middle East respiratory syndrome coronavirus
with host cells and increase infectivity. J. Virol.
2020, 94, 426–446. 10.1128/JVI.00426-20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.00426-20</ArticleId>
            <ArticleId IdType="pmc">PMC7307142</ArticleId>
            <ArticleId IdType="pubmed">32295925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khelashvili G.; Plante A.; Doktorova M.; Weinstein H.
Ca2+-dependent mechanism of membrane insertion and destabilization by the
SARS-CoV-2 fusion peptide. Biophys. J.
2021, 120, 1105–1119. 10.1016/j.bpj.2021.02.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bpj.2021.02.023</ArticleId>
            <ArticleId IdType="pmc">PMC7899928</ArticleId>
            <ArticleId IdType="pubmed">33631204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lai A. L.; Freed J. H.
SARS-CoV-2 Fusion Peptide has a Greater Membrane Perturbating Effect than
SARS-CoV with Highly Specific Dependence on Ca2+. J. Mol. Biol.
2021, 433, 166946.10.1016/j.jmb.2021.166946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jmb.2021.166946</ArticleId>
            <ArticleId IdType="pmc">PMC7969826</ArticleId>
            <ArticleId IdType="pubmed">33744314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kurokawa J.; Adachi-Akahane S.; Nagao T.
1,5-benzothiazepine binding domain is located on the extracellular side of
the cardiac L-type Ca2+ channel. Mol. Pharmacol.
1997, 51, 262–268. 10.1124/mol.51.2.262.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/mol.51.2.262</ArticleId>
            <ArticleId IdType="pubmed">9203631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hockerman G. H.; Johnson B. D.; Scheuer T.; Catterall W. A.
Molecular determinants of high affinity phenylalkylamine block of L-type
calcium channels. J. Biol. Chem.
1995, 270, 22119–22122. 10.1074/jbc.270.38.22119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.270.38.22119</ArticleId>
            <ArticleId IdType="pubmed">7673189</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee K. S.; Tsien R. W.
Mechanism of calcium channel blockade by verapamil, D600, diltiazem and
nitrendipine in single dialysed heart cells. Nature
1983, 302, 790–794. 10.1038/302790a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/302790a0</ArticleId>
            <ArticleId IdType="pubmed">6302512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Genazzani A A; Mezna M; Dickey D M; Michelangeli F; Walseth T F; Galione A
Pharmacological properties of the Ca2+-release mechanism sensitive to NAADP
in the sea urchin egg. Br. J. Pharmacol.
1997, 121, 1489–1495. 10.1038/sj.bjp.0701295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjp.0701295</ArticleId>
            <ArticleId IdType="pmc">PMC1564845</ArticleId>
            <ArticleId IdType="pubmed">9257932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calcraft P. J.; Ruas M.; Pan Z.; Cheng X.; Arredouani A.; Hao X.; Tang J.; Rietdorf K.; Teboul L.; Chuang K. T.; Lin P.; Xiao R.; Wang C.; Zhu Y.; Lin Y.; Wyatt C. N.; Parrington J.; Ma J.; Evans A. M.; Galione A.; Zhu M. X.
NAADP mobilizes calcium from acidic organelles through two-pore
channels. Nature
2009, 459, 596–600. 10.1038/nature08030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature08030</ArticleId>
            <ArticleId IdType="pmc">PMC2761823</ArticleId>
            <ArticleId IdType="pubmed">19387438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakurai Y.; Kolokoltsov A. A.; Chen C. C.; Tidwell M. W.; Bauta W. E.; Klugbauer N.; Grimm C.; Wahl-Schott C.; Biel M.; Davey R. A.
Two-pore channels control Ebola virus host cell entry and are drug targets
for disease treatment. Science (Washington, DC, U. S.)
2015, 347, 995–998. 10.1126/science.1258758.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1258758</ArticleId>
            <ArticleId IdType="pmc">PMC4550587</ArticleId>
            <ArticleId IdType="pubmed">25722412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Löfdahl C.-G.; Barnes P. J.
Calcium, Calcium Channel Blockade and Airways Function. Acta Pharmacol. Toxicol.
1986, 58, 91–111. 10.1111/j.1600-0773.1986.tb02525.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-0773.1986.tb02525.x</ArticleId>
            <ArticleId IdType="pubmed">2872771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du W.; McMahon T. J.; Zhang Z. S.; Stiber J. A.; Meissner G.; Eu J. P.
Excitation-contraction coupling in airway smooth muscle. J. Biol. Chem.
2006, 281, 30143–30151. 10.1074/jbc.M606541200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M606541200</ArticleId>
            <ArticleId IdType="pubmed">16891657</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flores-Soto E.; Reyes-García J.; Sommer B.; Montaño L. M.
Sarcoplasmic reticulum Ca2+ refilling is determined by L-type Ca2+ and
store operated Ca2+ channels in guinea pig airway smooth muscle. Eur. J. Pharmacol.
2013, 721, 21–28. 10.1016/j.ejphar.2013.09.060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejphar.2013.09.060</ArticleId>
            <ArticleId IdType="pubmed">24113526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiu K. Y.; Li J. G.; Lin Y.
Calcium channel blockers for lung function improvement in asthma: A
systematic review and meta-analysis. Ann. Allergy, Asthma, Immunol.
2017, 119, 518–523.e3. 10.1016/j.anai.2017.08.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.anai.2017.08.013</ArticleId>
            <ArticleId IdType="pubmed">29032888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cashman D. P.
Why the lower reported prevalence of asthma in patients diagnosed with
COVID-19 validates repurposing EDTA solutions to prevent and manage treat COVID-19
disease. Med. Hypotheses
2020, 144, 110027.10.1016/j.mehy.2020.110027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mehy.2020.110027</ArticleId>
            <ArticleId IdType="pmc">PMC7319607</ArticleId>
            <ArticleId IdType="pubmed">32758873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Solaimanzadeh I.
Nifedipine and Amlodipine Are Associated With Improved Mortality and
Decreased Risk for Intubation and Mechanical Ventilation in Elderly Patients
Hospitalized for COVID-19. Cureus
2020, 12, e8068–e8069. 10.7759/cureus.8069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7759/cureus.8069</ArticleId>
            <ArticleId IdType="pmc">PMC7219014</ArticleId>
            <ArticleId IdType="pubmed">32411566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Millet J. K.; Tang T.; Nathan L.; Jaimes J. A.; Hsu H. L.; Daniel S.; Whittaker G. R.
Production of pseudotyped particles to study highly pathogenic
coronaviruses in a biosafety level 2 setting. J. Visualized Exp.
2019, 2019, e5901010.3791/59010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3791/59010</ArticleId>
            <ArticleId IdType="pmc">PMC6677141</ArticleId>
            <ArticleId IdType="pubmed">30882796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsuyama S.; Nagata N.; Shirato K.; Kawase M.; Takeda M.; Taguchi F.
Efficient Activation of the Severe Acute Respiratory Syndrome Coronavirus
Spike Protein by the Transmembrane Protease TMPRSS2. J. Virol.
2010, 84, 12658–12664. 10.1128/JVI.01542-10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.01542-10</ArticleId>
            <ArticleId IdType="pmc">PMC3004351</ArticleId>
            <ArticleId IdType="pubmed">20926566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawase M.; Shirato K.; van der Hoek L.; Taguchi F.; Matsuyama S.
Simultaneous Treatment of Human Bronchial Epithelial Cells with Serine and
Cysteine Protease Inhibitors Prevents Severe Acute Respiratory Syndrome Coronavirus
Entry. J. Virol.
2012, 86, 6537–6545. 10.1128/JVI.00094-12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.00094-12</ArticleId>
            <ArticleId IdType="pmc">PMC3393535</ArticleId>
            <ArticleId IdType="pubmed">22496216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujioka Y.; Tsuda M.; Nanbo A.; Hattori T.; Sasaki J.; Sasaki T.; Miyazaki T.; Ohba T.
A Ca2+-dependent signalling circuit regulates influenza A virus
internalization and infection. Nat. Commun.
2013, 4, 1–13. 10.1038/ncomms3763.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms3763</ArticleId>
            <ArticleId IdType="pubmed">24434940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nugent K. M.; Shanley J. D.
Verapamil inhibits influenza A virus replication. Arch. Virol.
1984, 81, 163–170. 10.1007/BF01309305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF01309305</ArticleId>
            <ArticleId IdType="pubmed">6743023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujioka Y.; Nishide S.; Ose T.; Suzuki T.; Kato I.; Fukuhara H.; Fujioka M.; Horiuchi K.; Satoh A. O.; Nepal P.; Kashiwagi S.; Wang J.; Horiguchi M.; Sato Y.; Paudel S.; Nanbo A.; Miyazaki T.; Hasegawa H.; Maenaka K.; Ohba Y.
A Sialylated Voltage-Dependent Ca 2+ Channel Binds Hemagglutinin and
Mediates Influenza A Virus Entry into Mammalian Cells. Cell Host Microbe
2018, 23, 809–818.e5. 10.1016/j.chom.2018.04.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chom.2018.04.015</ArticleId>
            <ArticleId IdType="pubmed">29779930</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lavanya M.; Cuevas C. D.; Thomas M.; Cherry S.; Ross S. R.
siRNA screen for genes that affect Junín virus entry uncovers
voltage-gated calcium channels as a therapeutic target. Sci. Transl. Med.
2013, 5, 204ra130–204ra131. 10.1126/scitranslmed.3006827.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.3006827</ArticleId>
            <ArticleId IdType="pmc">PMC4104171</ArticleId>
            <ArticleId IdType="pubmed">24068738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang S.; Liu Y.; Guo J.; Wang P.; Zhang L.; Xiao G.; Wang W.
Screening of FDA-Approved Drugs for Inhibitors of Japanese Encephalitis
Virus Infection. J. Virol.
2017, 91, 1.10.1128/JVI.01055-17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.01055-17</ArticleId>
            <ArticleId IdType="pmc">PMC5640845</ArticleId>
            <ArticleId IdType="pubmed">28814523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daniloski Z.; Jordan T. X.; Wessels H. H.; Hoagland D. A.; Kasela S.; Legut M.; Maniatis S.; Mimitou E. P.; Lu L.; Geller E.; Danziger O.; Rosenberg B. R.; Phatnani H.; Smibert P.; Lappalainen T.; tenOever B. R.; Sanjana N. E.
Identification of Required Host Factors for SARS-CoV-2 Infection in Human
Cells. Cell
2021, 184, 92–105.e16. 10.1016/j.cell.2020.10.030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2020.10.030</ArticleId>
            <ArticleId IdType="pmc">PMC7584921</ArticleId>
            <ArticleId IdType="pubmed">33147445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nathan L.; Lai A. L.; Millet J. K.; Straus M. R.; Freed J. H.; Whittaker G. R.; Daniel S.
Calcium ions directly interact with the ebola virus fusion peptide to
promote structure-function changes that enhance infection. ACS Infect. Dis.
2020, 6, 250–260. 10.1021/acsinfecdis.9b00296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acsinfecdis.9b00296</ArticleId>
            <ArticleId IdType="pmc">PMC7040957</ArticleId>
            <ArticleId IdType="pubmed">31746195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubé M.; Rey F. A.; Kielian M.
Rubella Virus: First Calcium-Requiring Viral Fusion Protein. PLoS Pathog.
2014, 10, e100453010.1371/journal.ppat.1004530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.ppat.1004530</ArticleId>
            <ArticleId IdType="pmc">PMC4256232</ArticleId>
            <ArticleId IdType="pubmed">25474548</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindenbach B. D.
Measuring HCV infectivity produced in cell culture and in
vivo. Methods Mol. Biol.
2009, 510, 329–336. 10.1007/978-1-59745-394-3_24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-59745-394-3_24</ArticleId>
            <ArticleId IdType="pubmed">19009272</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
